The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.
You don't have permission to access "http://www.medpagetoday.com/washington-watch/washington-watch/123652" on this server. Reference #18.d494d817.1793332899.22e6a54f https://errors.edgesuite.net/18.d494d817.1793332899.22e6a54f
3 min read IF ANYONE CAN MAKE RATTAN hot, it’s Alexander Skarsgård. The actor’s latest film project, about a craftsman who creates a wicker husband (Skarsgård) for a lonely woman (played by Olivia Colman), has been an unlikely hit since its release in theaters last week. But basket weave isn’t the only material Skarsgård’s rocking—he’s
PAGE, Ariz. — Doug Herrera still lives in the house his father built, though his dad died some time ago from cancer. Herrera wonders if that illness could have been linked to pollutants from nearby uranium mining. Now, he worries that a possible new neighbor — a proposed $10 billion mega data center — could
COVID REPORT: Only One New Case Confirmed for the Second Day in a Row, Joint Information Center Says
Press release from the Humboldt County Joint Information Center:
Humboldt County’s total number of confirmed COVID-19 cases now stands at 361, after one additional case was reported today.
Humboldt County Health Officer Dr. Teresa Frankovich said that reporting only one case for two days is welcome relief from recent periods of rapid increase. “Two days is not a trend, but once again, I want to thank the community for helping to keep our case counts favorable compared to many areas of the state and nation,” she said. “We all benefit when we are able to slow transmission of this virus, and doing so takes all of us remaining committed to wearing facial coverings, avoiding gatherings outside of our household units and practicing physical distancing at all times in public.”
Today’s alert level stands at three or level orange. Visit humboldtgov.org/dashboard to view the county’s Alert Level Assessment tool.
Humboldt County COVID-19 Data Dashboard: humboldtgov.org/dashboard, Follow us on Facebook: @HumCoCOVID19, Instagram: @HumCoCOVID19, Twitter: @HumCoCOVID19, and Humboldt Health Alert: humboldtgov.org/HumboldtHealthAlert
###
Today
=historic data. All data from the Humboldt County Joint Information Center.
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.
You don't have permission to access "http://www.medpagetoday.com/washington-watch/washington-watch/123652" on this server. Reference #18.d494d817.1793332899.22e6a54f https://errors.edgesuite.net/18.d494d817.1793332899.22e6a54f
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.
You don't have permission to access "http://www.medpagetoday.com/washington-watch/washington-watch/123652" on this server. Reference #18.d494d817.1793332899.22e6a54f https://errors.edgesuite.net/18.d494d817.1793332899.22e6a54f